Mixed Phenotype Acute Leukemia (MPAL)
3 clinical trials · Condition
◉ Watch Mixed Phenotype Acute Leukemia (MPAL)
| Record | Firm | Date |
|---|---|---|
| Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL) (NCT07222579) | West Virginia University | 2026-01-15 |
| Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL (NCT04827745) | University of Maryland, Baltimore | 2021-06-11 |
| Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome (NCT02212561) | St. Jude Children's Research Hospital | 2014-08-01 |
Track Mixed Phenotype Acute Leukemia (MPAL) automatically
Every clearance here is in the API, with alerts when new ones post.